| Nome |
# |
|
Measurement of the thickness of the urethrovaginal space in women with or without vaginal orgasm, file e291c0d4-be00-cddb-e053-3a05fe0aa144
|
5.471
|
|
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus calmette-guerin for non-muscle-invasive bladder cancer, file e291c0d4-be03-cddb-e053-3a05fe0aa144
|
1.011
|
|
The stability of lidocaine and epinephrine solutions exposed to electric current and comparative administration rates of the two drugs into pig bladder wall., file e291c0d6-25e0-cddb-e053-3a05fe0aa144
|
803
|
|
Updates in intravesical electromotive drug administration(A (R)) of mitomycin-C for non-muscle invasive bladder cancer, file e291c0d4-be04-cddb-e053-3a05fe0aa144
|
793
|
|
Intravesical therapy with mitomycin through electromotive drug administration., file e291c0d4-bc1f-cddb-e053-3a05fe0aa144
|
659
|
|
New Frontiers in Intravesical Therapies and Drug Delivery, file e291c0d5-f966-cddb-e053-3a05fe0aa144
|
647
|
|
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial, file e291c0d5-fa02-cddb-e053-3a05fe0aa144
|
641
|
|
Electromotive drug administration (EMDA) with mitomycyn-C for non-muscle invasive bladder cancer., file e291c0d4-bdfe-cddb-e053-3a05fe0aa144
|
616
|
|
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial., file e291c0d4-bdcc-cddb-e053-3a05fe0aa144
|
604
|
|
The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome., file e291c0d4-a0ff-cddb-e053-3a05fe0aa144
|
531
|
|
Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels., file e291c0d6-2bc0-cddb-e053-3a05fe0aa144
|
523
|
|
Intravesical chemotherapy and chemohypherthermia in non-muscle-invasive bladder cancer; An overview on drug administration technologies and pharmacokinetics, file e291c0d6-e5c8-cddb-e053-3a05fe0aa144
|
519
|
|
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer, file e291c0d7-6b0a-cddb-e053-3a05fe0aa144
|
513
|
|
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study., file e291c0d4-bdfc-cddb-e053-3a05fe0aa144
|
504
|
|
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer, file e291c0d7-6b84-cddb-e053-3a05fe0aa144
|
494
|
|
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer, file e291c0d6-1d0c-cddb-e053-3a05fe0aa144
|
480
|
|
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients., file e291c0d6-22f5-cddb-e053-3a05fe0aa144
|
457
|
|
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study., file e291c0d6-22f1-cddb-e053-3a05fe0aa144
|
441
|
|
A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease., file e291c0d6-2bb9-cddb-e053-3a05fe0aa144
|
431
|
|
Intravesical electro-osmotic administration of mitomycin C, file e291c0d6-1489-cddb-e053-3a05fe0aa144
|
388
|
|
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought, file e291c0d7-6b82-cddb-e053-3a05fe0aa144
|
384
|
|
Metastasis-free survival is a strong Surrogate of overall survival in localized prostate cancer, file e291c0d6-e452-cddb-e053-3a05fe0aa144
|
378
|
|
Pelvic floor muscle behavior during Valsalva leak point pressure measurement in males and females affected by stress urinary incontinence., file e291c0d6-2d17-cddb-e053-3a05fe0aa144
|
375
|
|
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study, file e291c0d7-6cc6-cddb-e053-3a05fe0aa144
|
370
|
|
Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study., file e291c0d6-2947-cddb-e053-3a05fe0aa144
|
366
|
|
Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens., file e291c0d4-c1a8-cddb-e053-3a05fe0aa144
|
354
|
|
Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study, file e291c0d5-fac6-cddb-e053-3a05fe0aa144
|
353
|
|
Intermittent catheterization with a prelubricated catheter in spinal cord injured patients: A prospective randomized crossover study, file e291c0d6-214f-cddb-e053-3a05fe0aa144
|
353
|
|
Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study., file e291c0d6-2806-cddb-e053-3a05fe0aa144
|
326
|
|
The in vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agents: the ONCOFID-P(R) paradigm, file e291c0d4-bdca-cddb-e053-3a05fe0aa144
|
313
|
|
Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity, file e291c0d5-f969-cddb-e053-3a05fe0aa144
|
299
|
|
Ontogenetic profile and thyroid hormone regulation of type-1 and type-8 glucose transporters in rat Sertoli cells., file e291c0d6-20d8-cddb-e053-3a05fe0aa144
|
287
|
|
Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin., file e291c0d6-2c2a-cddb-e053-3a05fe0aa144
|
287
|
|
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: surgical, oncological, and functional outcomes: a systematic review., file e291c0d4-c301-cddb-e053-3a05fe0aa144
|
283
|
|
Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens, file e291c0d6-239e-cddb-e053-3a05fe0aa144
|
277
|
|
Cavernous hemangioma of the renal hilum presenting as an avascularized solid mass., file e291c0d6-22ed-cddb-e053-3a05fe0aa144
|
273
|
|
Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer, file e291c0d4-be07-cddb-e053-3a05fe0aa144
|
262
|
|
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy, file e291c0d7-6cc4-cddb-e053-3a05fe0aa144
|
244
|
|
Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy, file e291c0d6-ee3f-cddb-e053-3a05fe0aa144
|
243
|
|
The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis., file e291c0d5-a13a-cddb-e053-3a05fe0aa144
|
230
|
|
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial, file e291c0d5-fe95-cddb-e053-3a05fe0aa144
|
217
|
|
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin, file e291c0d5-fe96-cddb-e053-3a05fe0aa144
|
206
|
|
Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder, file e291c0d5-f39f-cddb-e053-3a05fe0aa144
|
203
|
|
Urodynamic assessment of bladder and urethral sphincter function before radical prostatectomy and during long-term follow-up., file e291c0d6-2809-cddb-e053-3a05fe0aa144
|
203
|
|
Celecoxib for the prevention of nonmuscle invasive bladder cancer: Results from a matched control study, file e291c0d5-f3a1-cddb-e053-3a05fe0aa144
|
201
|
|
Localised prostate cancer and hemophilia A (AHA):
Case report and management of the disease., file e291c0d4-9a88-cddb-e053-3a05fe0aa144
|
199
|
|
Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens, file e291c0d5-867e-cddb-e053-3a05fe0aa144
|
172
|
|
Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer., file e291c0d7-5ae0-cddb-e053-3a05fe0aa144
|
157
|
|
The splicing factor PTBP1 promotes expression of oncogenic splice variants and predicts poor prognosis in patients with non-muscle-invasive bladder cancer, file e291c0d7-6849-cddb-e053-3a05fe0aa144
|
147
|
|
Effects of onabotulinum toxin a intradetrusor injections on urinary symptoms and sexual life in women affected by multiple sclerosis: a prospective controlled study., file e291c0d7-4fb6-cddb-e053-3a05fe0aa144
|
146
|
|
Psychosocial issues of ART in aging male., file e291c0d6-28ea-cddb-e053-3a05fe0aa144
|
141
|
|
Intravesical electromotive administration of oxybutynin: from laboratoty to clinica field., file e291c0d6-2828-cddb-e053-3a05fe0aa144
|
99
|
|
The bladder urothelium: passive permeabilità and intravesical drug passive diffusion., file e291c0d6-256b-cddb-e053-3a05fe0aa144
|
93
|
|
Percutaneous sequential bacillus Calmette-Guèrin and mitomycin C for panurothelial carcinomatosis., file e291c0d6-2bb7-cddb-e053-3a05fe0aa144
|
87
|
|
Intravesical electromotive drug administration., file e291c0d6-228e-cddb-e053-3a05fe0aa144
|
79
|
|
The human bladder urothelium: new concepts and future perspectives., file e291c0d6-2290-cddb-e053-3a05fe0aa144
|
73
|
|
Detection and Clinical Significance of Circulating Tumor Cells in Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer, file e291c0d6-e787-cddb-e053-3a05fe0aa144
|
56
|
|
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients, file e291c0d9-de0a-cddb-e053-3a05fe0aa144
|
54
|
|
How can the COVID-19 pandemic lead to positive changes in urology residency?, file e291c0d8-ef2c-cddb-e053-3a05fe0aa144
|
53
|
|
T1 Bladder Cancer: Comparison of the Prognostic Impact of Two Substaging Systems on Disease Recurrence and Progression and Suggestion of a Novel Nomogram, file e291c0d9-abbb-cddb-e053-3a05fe0aa144
|
48
|
|
Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot stud, file e291c0d7-7505-cddb-e053-3a05fe0aa144
|
41
|
|
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer, file e291c0d7-698a-cddb-e053-3a05fe0aa144
|
40
|
|
Clinical outcomes of second-line Treatments cycling in refractory wet OAB patients before switching to intradetrusor injections of onabotulinumtoxin/A: a real world observational study, file e291c0d7-4f83-cddb-e053-3a05fe0aa144
|
38
|
|
T1 bladder cancer: comparison of the prognostic impact of two substaging systems on disease recurrence and progression and suggestion of a novel nomogram, file e291c0d9-c7f8-cddb-e053-3a05fe0aa144
|
23
|
|
The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: a retrospective multi-institutional cohort analysis, file e291c0d9-cf8f-cddb-e053-3a05fe0aa144
|
18
|
|
Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer., file e291c0d9-a552-cddb-e053-3a05fe0aa144
|
10
|
|
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis, file 3f559fb7-9d09-49d2-9614-240faf383e96
|
9
|
|
Celecoxib for the prevention of nonmuscle invasive bladder cancer: Results from a matched control study, file e291c0d9-1931-cddb-e053-3a05fe0aa144
|
7
|
|
T1 bladder cancer: comparison of the prognostic impact of two substaging systems of disease recurrence and progression and suggestion of a novel nomogram., file 566f5382-d21e-404a-9468-c44ebeb8ee36
|
6
|
|
Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma, file e291c0d8-6748-cddb-e053-3a05fe0aa144
|
5
|
|
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor., file e291c0d7-b0b1-cddb-e053-3a05fe0aa144
|
3
|
|
null, file e3894f77-a0ce-41e1-805f-5e76975e80fe
|
3
|
|
Platelet-derived growth factor regulation of type-5 phosphodiesterase in human and rat penile smooth muscle cells., file e291c0d5-60fd-cddb-e053-3a05fe0aa144
|
2
|
|
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor, file e291c0d8-4332-cddb-e053-3a05fe0aa144
|
2
|
|
The transcriptional terminator XRN2 and the RNA-binding protein Sam68 link alternative polyadenylation to cell cycle progression in prostate cancer, file f2c2fc7f-8acb-4be3-9ca7-98defb3eadc7
|
2
|
|
TOPICAL THERAPY: IONTOPHORESISAND ELECTROMOTIVE DRUG ADMNISTRATION, file 2a419690-23f3-46a0-b562-28922ba60d95
|
1
|
|
Percutaneous intervention therapy for vascular erectile dysfunction|Il trattamento interventistico percutaneo può risolvere la disfunzione erettile vasculogenica, file e291c0d8-84b8-cddb-e053-3a05fe0aa144
|
1
|
|
Athermal versus ultrasonic nerve-sparing laparoscopic radical prostatectomy: a comparison of functional and oncological outcomes, file e291c0d8-ad1f-cddb-e053-3a05fe0aa144
|
1
|
| Totale |
25.629 |